-- サン・ライフ・フィナンシャル(SLF.TO)は木曜日の取引終了後、1980年代と1990年代にメットライフが販売・発行した個人生命保険契約に関する集団訴訟について、原則的な和解に達したと発表した。サン・ライフは買収を通じてこれらの契約を引き継いだ。 同社によると、この訴訟はサン・ライフが販売した保険契約や商品とは一切関係がない。 和解が承認されれば、サン・ライフは対象となる保険契約者に対し、最大2億1350万ドルの和解金を支払うことになる。これにより、2026年第1四半期の報告済み純利益に約1億4500万ドルの費用が発生する見込みだ。 訴訟は、メットライフからの補償の対象となる保険契約の条項の解釈に関するものだ。サン・ライフは、和解が承認された場合、補償に基づきメットライフに対して全面的に賠償を求めると明言した。 また、AM Bestは、サン・ライフ・フィナンシャルの中核保険子会社であるサン・ライフ・アシュアランス・カンパニー・オブ・カナダおよびサン・ライフ・アンド・ヘルス・インシュアランス・カンパニー(米国)の財務力格付け(FSR)をA+(優良)、長期発行体信用格付け(長期ICR)を「aa」(優良)に据え置きました。さらに、AM Bestはサン・ライフ・フィナンシャル(SLF)の長期ICRを「a」(優秀)、長期発行体信用格付け(長期IR)も据え置きました。これらの格付けの見通しは安定的です。 これらの格付けは、AM Bestが「最も強固」と評価するサン・ライフ・グループのバランスシートの健全性、堅調な事業実績、良好な事業プロファイル、そして非常に強固な企業リスク管理を反映しています。 サン・ライフ・フィナンシャルの株価は、米国時間外取引で72.08米ドルで横ばいでした。トロント証券取引所では1.30米ドル高の97.87米ドルで取引を終えました。
Related Articles
Research Alert: CFRA Reiterates Sell Opinion On Shares Of Hilton Worldwide Holdings Inc
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target by $9 to $293, or 32x our 2026 EPS estimate (unchanged) and in line with shares' five-year average forward multiple. We raise our 2026 EPS estimate to $9.16 from $8.88 and lower 2027's to $10.03 from $10.20. Following Q1 results that beat expectations and included raised guidance, we maintain our 2-STARS (Sell) rating. U.S. RevPAR performance broadened from primarily luxury and upper upscale segments to include more meaningful midscale contribution, which management attributes to the return of middle- and low-income consumers. However, we note Q1 results also included ADR deceleration, particularly among luxury hotels, which historically drive significant profit contribution. HLT's Q2 EBITDA guidance of $1,015-$1,035 million being below the $1,081 million consensus suggests luxury pricing power is weakening faster than midscale volume can offset. While the broadening demand trend is positive, we believe slowing luxury tailwinds limit upside at current valuation levels.
Research Alert: CFRA Maintains Buy Rating On Shares Of Universal Health Services
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $200 from $243, reflecting an 8.7x multiple of our 2026 EPS estimate, below peer multiples and a discount to UHS's five-year historical forward average of 11.9x. We lower our 2026 EPS forecast to $22.95 from $23.39 and cut our 2027 view to $25.48 from $25.67. Q1 inpatient volumes were flat on a same-facility basis, with seasonal headwinds from unfavorable winter weather and a milder flu/respiratory illness period. The recent expiration of ACA EPTCs also posed challenges, as UHS estimates a near 5% drop in ACA adjusted admissions relative to Q1 2025. UHS maintained its prior forecast of a 25%-30% decline in ACA exchange volumes during the full year, which represented around 6% of the acute care business adjusted admissions in 2025 and under 5% of the acute care segment revenues. UHS anticipates a $75M pre-tax earnings hit in 2026 from these developments, unchanged from prior guidance.
Briscoe Group Fiscal Q1 Sales Tick Higher
Briscoe Group (NZE:BGP, ASX:BGP) said its sales for the fiscal first quarter ended April 26 increased over 1% year over year to NZ$180.8 million, according to Friday filings with the Australian and New Zealand bourses.Sales in the company's homeware segment rose 2% to NZ$105.7 million, and sporting goods sales edged 0.5% higher to NZ$75.1 million.The company said discretionary consumer spending has dampened due to the Middle East conflict, with a noticeable impact on the retail sector during the latter part of the quarter, while bad weather in New Zealand also had a negative impact on store traffic.